Please join us for a virtual webinar on Wednesday, July 30th from 8:00-9:00 p.m. EST. titled “Not All Obesity is the Same – A Look at Obesities Caused by Rare Neuroendocrine Diseases,” hosted by Angela Fitch MD, FACP, FOMA, Founder and Chief Medical Officer of Knownwell. This webinar is intended for US healthcare professionals. To register, please visit: https://bit.ly/4567PMk
About us
Rhythm Pharmaceuticals is a global, commercial-stage biopharmaceutical company focused on transforming the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause. The Company develops medicines for previously untreatable or undertreated diseases and provides meaningful support for healthcare providers and patients and their families. In addition to commercializing its lead asset in North America, Europe and other regions, Rhythm is advancing a broad clinical development program in rare MC4R pathway diseases, as well as investigational MC4R agonists, and a preclinical suite of small molecules for the treatment of congenital hyperinsulinism. At Rhythm, we know our work makes an important difference in the lives of patients and their families around the world. Every employee contributes to the company’s goal of discovering new treatments for rare diseases that no other company is developing. As a fast-growing company with an exciting future, we offer a collaborative environment where employees’ contributions truly matter, which is one of the many reasons we were recognized as one of The Boston Globe’s Top Places to Work in Massachusetts for 2023 and 2024.
- Website
-
http://www.rhythmtx.com
External link for Rhythm Pharmaceuticals Inc.
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Boston, MA
- Type
- Public Company
- Founded
- 2008
- Specialties
- genetics, obesity, peptides, metabolism, rare disease, biotechnology, Pharmaceuticals, Research, Health, Medicine, Clinical Trials, Endocrinology, Orphan disease, Science, Advocacy, Epidemiology, Orphan drugs, Rare disease, and metabolic
Locations
-
Primary
Get directions
222 Berkeley Street, 12th Floor
Boston, MA 02116, US
Employees at Rhythm Pharmaceuticals Inc.
Updates
-
Acquired hypothalamic obesity carries a significant, long-term physical burden for people with hypothalamic injury. Learn about the correlation between increased weight and decreased quality of life for patients with acquired HO and their caregivers on DifferentObesity.com.
-
-
The Rhythm team is excited for #ENDO2025! On Saturday, July 12 and Monday, July 14 we will present data related to our research on acquired hypothalamic obesity. Learn more here: https://bit.ly/3IdkOmt
-
-
We look forward to engaging with researchers and clinicians in the endocrinology field at the Endocrine Society's annual Meeting, #ENDO2025, taking place July 12-15 in San Francisco! Please visit Rhythm’s medical booth (1101), commercial booth (1200) and disease education booth (1103) to learn more about our work to help patients living with #hyperphagia and severe #obesity caused by rare neuroendocrine diseases.
-
-
Today Rhythm announced positive results from our Phase 2 trial in acquired hypothalamic obesity. Read more details in our press release: https://bit.ly/3Gy2Tq9
-
-
📣#TalentTuesday📣 Meet @Kristina Barakov, a member of our global medical communications team! Kristina and all of our Rhythm colleagues play a crucial role in bringing our mission to transform the lives of patients living with rare neuroendocrine diseases to life. Learn more about Rhythm’s mission and people: https://lnkd.in/ejR3hmtZ #BiotechCareers #Hiring
-
-
The Rhythm team is excited for #ENDO2025 in San Francisco! On Monday, July 14 from 12:30-1:30p.m., Rhythm will sponsor a symposium titled, “Understanding Acquired Hypothalamic Obesity, A Rare Neuroendocrine Disease,” hosted by Odelia Cooper, MD, Diabetes & Metabolism Endocrinologist at Cedars Sinai Medical Center, and Ilene Fennoy, MD, Pediatric Endocrinologist at Columbia Irving Medical Center.
-
-
We are excited to announce the launch of ho.differentobesity.com, a comprehensive, easy-to-navigate site tailored to survivors and caregivers in the US managing acquired hypothalamic obesity. To learn more about this rare form of obesity caused by injury to the hypothalamus, and access educational materials, visit: ho.differentobesity.com
-
-
Thank you to the American Diabetes Association for a fantastic #ADA2025! Rhythm enjoyed connecting with endocrinology professionals and sharing more about our mission to transform the lives of patients living with obesity due to rare neuroendocrine diseases.
-
-
📣#TalentTuesday📣 Meet Tiffany Correll, a Senior Territory Manager at Rhythm! Tiffany and the rest of the TM team play a crucial role in bringing our mission to transform the lives of patients living with rare neuroendocrine diseases to life. Learn more about Rhythm’s mission and our open positions here: https://lnkd.in/e7nRnSZu #BiotechCareers #Hiring
-